Every 10-Q that Elevance Health Inc (ELV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELV filings page.
Elevance Health reported total revenues of $50,474M for the quarter ended June 30, 2026, slightly above $49,776M a year earlier. Shareholders’ net income declined to $1,463M from $1,743M, with diluted EPS of $6.71 versus $7.72, as benefit, product and operating expenses grew faster than revenue. For the first half, shareholders’ net income was $3,227M compared with $3,926M, and diluted EPS was $14.73.
Cash generation strengthened, with net cash from operating activities of $6,245M in the first six months, up from $3,071M, helping lift cash and equivalents to $10,232M. Total assets were $126,438M and shareholders’ equity rose to $44,883M, while long-term debt decreased slightly to $31,044M.
The company is executing a 2026–2027 Operating Model Transformation Program, incurring $129M of primarily personnel-related costs and carrying a related liability of $114M. It also recorded a $935M operating expense accrual for Medicare Advantage risk‑adjustment data, paid $342M to CMS, and ended the quarter with a $593M remaining liability, with management citing a reasonably possible range of approximately ±$320M around the initial estimate.
Elevance Health reported higher first-quarter 2026 revenue but lower profit as it absorbed large Medicare and restructuring charges. Total revenues rose to $50.2 billion from $48.9 billion a year earlier, driven mainly by premiums of $41.0 billion and product revenue of $6.2 billion.
Net income fell to $1.8 billion from $2.2 billion, with diluted earnings per share declining to $8.00 from $9.61. Results included a $935 million accrual tied to Medicare Advantage risk-adjustment data the company previously submitted to CMS, where the ultimate liability could be between $585 million lower and $565 million higher than the amount accrued. Elevance also booked $129 million of costs under a new 2026–2027 Operating Model Transformation Program aimed at simplifying its organization and expanding technology use.
Despite these charges, operations generated $4.3 billion of cash, up sharply from $1.0 billion a year earlier. The company repurchased 3.7 million shares for $1.1 billion at an average price of $304.68 and paid dividends of $1.72 per share, while total shareholders’ equity held roughly steady at $43.9 billion.
Elevance Health (ELV) reported stronger Q3 2025 results. Total revenues were $50.711 billion versus $45.106 billion a year ago, driven by premiums of $41.791 billion (up from $36.809 billion), product revenue of $6.159 billion, and service fees of $2.137 billion. Shareholders’ net income rose to $1.189 billion from $1.016 billion, and diluted EPS increased to $5.32 from $4.36.
For the first nine months, total revenues reached $149.378 billion versus $131.569 billion, while shareholders’ net income was $5.115 billion versus $5.562 billion. Operating cash flow was $4.206 billion versus $5.102 billion.
On the balance sheet, cash and cash equivalents were $8.713 billion, total assets $122.749 billion, and total shareholders’ equity improved to $43.953 billion with accumulated other comprehensive loss narrowing to $(543) million from $(1,147) million. Long-term debt rose to $31.173 billion. The company repurchased $2.134 billion of common stock year-to-date and paid $1.152 billion in dividends. Shares outstanding were 222,238,763 as of October 14, 2025.
Recent acquisitions of Centers and CareBridge were integrated; purchase accounting remains open, with associated goodwill and intangibles recorded.